Individualized anemia management enhanced by ferric pyrophosphate citrate protocol

The optimal use of erythropoiesis-stimulating agents (ESAs) and parenteral iron in managing anemia in end-stage renal disease (ESRD) remains controversial. One-size-fits-all rule-based algorithms dominate dosing protocols for ESA and parenteral iron. However, the Food & Drug Administration (FDA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chait, Yossi, Nathanson, Brian H., Germain, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684411/
https://www.ncbi.nlm.nih.gov/pubmed/36418453
http://dx.doi.org/10.1038/s41598-022-23262-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684411/
https://www.ncbi.nlm.nih.gov/pubmed/36418453
http://dx.doi.org/10.1038/s41598-022-23262-1

Ejemplares similares